Turning the Tide on Cancer

Cardiff Oncology is a clinical-stage company with the singular mission of developing new treatment options for cancer patients. Our goal is to overcome resistance, extend duration of response and increase overall survival.

focusing on cancer indications with the greatest medical need for new treatments

Featured News & Events

Feb 11, 2021

Cardiff Oncology Presents Phase 2 mCRPC Trial Data Showing a Two-Fold Increase in Efficacy with an Optimized Onvansertib Dosing Schedule

Jan 26, 2021

Cardiff Oncology Receives "Study May Proceed" from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Jan 15, 2021

Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program

Targeting a Key Regulatory Enzyme in Tumor Cell Division

We are developing onvansertib, an oral and highly selective inhibitor of polo-like kinase 1 (PLK1), which is over expressed in most cancers.

Our Clinical Programs

Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.

KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Combining onvansertib with decitabine to provide a new treatment option to improve efficacy and increase overalll survival.